# Glucagen Injection Market

> Glucagen Injection Market Research Report Information By Application (Therapeutic purpose and Diagnostics purpose), By Age group (Paediatrics and Adults), By Route of Administration (Subcutaneous, Intramuscular and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.63%
- **2024:** $ 0.26 Billion
- **2025:** $ 0.28 Billion
- **2035:** $ 0.48 Billion
- **Key Players:** Novo Nordisk (DK), Sanofi (FR), Eli Lilly and Company (US), Boehringer Ingelheim (DE), Pfizer (US), Amgen (US), Bristol-Myers Squibb (US), Mylan (US)

**Report ID:** MRFR/HC/19117-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/glucagen-injection-market-20665

---

## Market Summary

## **Global Glucagen Injection Market Overview**

As per MRFR analysis, the Glucagen Injection Market Size was estimated at 0.26 (USD Billion) in 2024. The Glucagen Injection Market Industry is expected to grow from 0.28 (USD Billion) in 2025 to 0.46 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.63% during the forecast period (2025 - 2034). An increase in patient education and awareness and increasing technological innovations are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Glucagen Injection Market Trends**

Market access and affordability play a crucial role in driving the Glucagen injection market by ensuring widespread availability and accessibility of this life-saving emergency treatment for severe hypoglycemia. Efforts to enhance patient access involve collaborations with healthcare systems, insurance providers, and patient assistance programs. Initiatives to make Glucagen more affordable for individuals with diabetes contribute to increased adoption. As affordability barriers decrease, more patients and caregivers can obtain and utilize Glucagen, promoting its use in emergency situations.

This focus on accessibility aligns with the broader goal of improving diabetes care and patient outcomes, shaping the Glucagen injection market and reinforcing its position as a critical intervention in managing severe hypoglycemia.

The increase in patient education and awareness is driving the Glucagen injection market by fostering a better understanding of the importance of emergency hypoglycemia management. Educational initiatives aimed at healthcare professionals and patients emphasize the role of Glucagen in severe hypoglycemia situations, empowering individuals and caregivers to respond effectively. Awareness campaigns highlight the significance of having Glucagen readily available and the proper administration techniques. As knowledge spreads, there is an elevated recognition of Glucagen's role in diabetes care, driving increased prescriptions and adoption.

The concerted efforts to educate and raise awareness contribute to a proactive approach in managing severe hypoglycemia, ultimately propelling the growth of the Glucagen injection market.

The increase in technological advances is driving the Glucagen injection market by fostering innovation in delivery methods and formulations. Ongoing research and development focus on creating more sophisticated and user-friendly devices for administering glucagon during severe hypoglycemic episodes. Advanced technologies may lead to the development of novel formulations, improving stability and ease of use. These technological advancements address existing limitations and enhance the overall patient experience, driving increased adoption of Glucagen.

As technological innovation continues, the market benefits from improved product efficacy, streamlined administration processes, and heightened patient confidence, solidifying Glucagen's role as a vital emergency treatment for severe hypoglycemia in the evolving landscape of diabetes care.

For instance, as reported by the International Diabetes Federation (IDF), the global adult diabetes population is estimated to be around 537 million in 2021, with a projected increase to 643 million by the year 2030. Thus, driving the Glucagen Injection market revenue.

## **Glucagen Injection Market Segment Insights**

### **Glucagen Injection Application Insights**

The Glucagen Injection Market segmentation, based on application includes Therapeutic purpose and Diagnostics purpose. The Therapeutic purpose segment dominated the market, accounting for 60% of market revenue (xx Billion). In developing economies, category growth is driven by an expanding overweight population and increased consumer knowledge of low-calorie beverages. Therapeutic purpose applications have secured the largest market share in the Glucagen Injection market due to their critical role in emergency treatment for severe hypoglycemia and diagnostic procedures. Glucagen Injections are widely utilized in clinical settings, emergency response, and hospital environments to swiftly elevate blood sugar levels.

Their vital role in managing hypoglycemic episodes and facilitating medical diagnostics has positioned therapeutic purpose applications as the preferred choice, driving their dominance in the market for Glucagen Injections.

Diagnostics purpose applications are experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to their increasing adoption for [medical imaging](../../../reports/medical-imaging-market-1995) procedures such as MRI scans. The use of Glucagen Injections as a contrast agent in diagnostic imaging has expanded their application, leading to a notable rise in demand. The versatility of Glucagen Injections for diagnostic purposes, particularly in radiology and imaging, has contributed to their substantial CAGR growth within the market for contrast agents and diagnostic aids.

### **Glucagen Injection Age Group Insights**

The Glucagen Injection Market segmentation, based on age group, includes Paediatrics and Adults. The Paediatrics category generated the most income (64%). The paediatrics age group has secured the largest market share in the Glucagen Injection market due to the critical need for rapid blood sugar elevation in paediatric emergency situations such as severe hypoglycemia. Glucagen Injections are vital in addressing acute hypoglycemic episodes in children, making them a primary choice for this demographic.

The specific requirements for paediatric emergency care and the prevalence of pediatric hypoglycemic incidents have led to the dominance of this age group in the market for Glucagen Injections.

The adult age group is experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to expanding utilization in emergency medical response and diagnostic procedures among adults. The increasing prevalence of conditions requiring rapid blood sugar elevation and the rising use of Glucagen Injections for diagnostic purposes in adult populations have contributed to this notable growth. Additionally, the aging demographic and a greater focus on adult healthcare have further propelled the demand for Glucagen Injections among adults, leading to the highest CAGR in this market segment.

### **Glucagen Injection Route of administration Insights**

The Glucagen Injection Market segmentation, based on Route of administration, includes Subcutaneous, Intramuscular and Intravenous. The subcutaneous category generated the most income (35.4%). The subcutaneous route of administration has secured the largest market share in the Glucagen Injection market due to its ease of use and effectiveness in delivering rapid blood sugar elevation. This method offers quick absorption and is well-suited for emergency situations, making it the preferred choice for administering Glucagen Injections. The simplicity and swiftness of subcutaneous administration, particularly in urgent hypoglycemic scenarios, have contributed to its dominance in the market for Glucagen Injections.

The intramuscular route of administration is experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to its increasing adoption in emergency medical settings and diagnostic procedures. This route offers rapid absorption and is preferred for its versatility in various clinical scenarios, contributing to its notable growth. The expanding use of intramuscular administration for Glucagen Injections in emergency response and diagnostic applications has led to its substantial CAGR within the market for these critical medical interventions.

### **Glucagen Injection Distribution channel Insights**

The Glucagen Injection Market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The online pharmacies category generated the most income (42%). Online pharmacies have secured the largest market share in the Glucagen Injection market due to their convenience, accessibility, and ability to reach a broad customer base. The ease of ordering, coupled with swift delivery services, has made online pharmacies a preferred choice for obtaining critical medications like Glucagen Injections.

Additionally, the increasing reliance on online platforms for healthcare products, particularly during the ongoing shift towards digital channels, has contributed to the dominance of online pharmacies in the market for Glucagen Injections.

Hospital pharmacies are experiencing the highest compound annual growth rate (CAGR) in the Glucagen Injection market due to the rising demand within hospital settings for emergency care and diagnostic procedures. The crucial role of Glucagen Injections in addressing acute hypoglycemia and supporting various medical imaging and diagnostic processes has led to their increased utilization within hospital pharmacies. This heightened reliance on hospital-based distribution channels for Glucagen Injections has propelled the notable CAGR growth within this segment of the market.

**Figure 1: Glucagen Injection Market, by Distribution channel, 2022 & 2032 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

**Glucagen Injection Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World.  North America has captured the largest market share in the Glucagen Injection market due to factors such as a high prevalence of diabetes, well-established healthcare infrastructure, and a significant focus on emergency care. The region's advanced healthcare systems, widespread awareness of diabetes management, and accessibility to emergency medications contribute to the dominance of Glucagen. Additionally, the proactive approach toward diabetes education and the large patient population with diabetes in North America solidify its position as a key consumer of Glucagen injections.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: GLUCAGEN INJECTION MARKET SHARE BY REGION 2022 (USD Billion)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe has captured the second-largest market share in the Glucagen Injection market due to factors such as a substantial diabetic population, well-developed healthcare systems, and a proactive approach to emergency care. The region's robust healthcare infrastructure, coupled with high awareness among healthcare professionals and patients, contributes to the significant use of Glucagen. Additionally, stringent regulatory standards ensure the availability and accessibility of Glucagen, solidifying Europe's position as a substantial consumer of emergency hypoglycemia treatment. Further, the German Glucagen Injection market held the largest market share, and the UK Glucagen Injection market was the fastest growing market in the European region

The Asia Pacific region is growing at the highest Compound Annual Growth Rate (CAGR) in the Glucagen Injection market due to increasing diabetes prevalence, rising healthcare awareness, and improving healthcare infrastructure. The region's large and diverse population, coupled with a growing emphasis on emergency care and diabetes management, contributes to the robust adoption of Glucagen. As healthcare facilities expand and awareness campaigns intensify, the Asia Pacific region demonstrates significant growth potential, positioning it as a key contributor to the increasing CAGR in the Glucagen Injection market.

Moreover, China’s Glucagen Injection market held the largest market share, and the Indian Glucagen Injection market was the fastest growing market in the Asia-Pacific region.

**Glucagen Injection Key Market Players & Competitive Insights**

Leading market players in the Glucagen Injection market are focused on strategic initiatives such as product development, geographic expansion, and collaborations. These companies actively engage in research and development to enhance glucagon formulations and delivery methods. Marketing developments emphasize the importance of Glucagen in diabetes emergency care. Collaborations with healthcare providers and institutions enhance the overall competitiveness. Efforts are directed towards maintaining product quality, meeting regulatory standards, and expanding market reach, ensuring a strong presence in the evolving landscape of the Glucagen Injection market.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Glucagen Injection industry to benefit clients and increase the market sector. In recent years, the Glucagen Injection industry has offered some of the most significant advantages to medicine. Major players in the Glucagen Injection market, including General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., and others, are attempting to increase market demand by investing in research and development operations.

Novo Nordisk is a major player in the Glucagen Injection market, emphasizing its commitment to [diabetes care](../../../reports/needle-free-diabetes-care-market-912). As a leading pharmaceutical company, Novo Nordisk produces GlucaGen, a glucagon injection used for emergency treatment of severe hypoglycemia in individuals with diabetes. The company's business strategy involves continuous research and development, ensuring product quality, and expanding its global presence. Novo Nordisk's comprehensive approach to diabetes management, including emergency interventions like GlucaGen, solidifies its position in the market. The company's dedication to innovation, patient-centric solutions, and collaborative efforts with healthcare professionals contribute to its significant role in shaping the Glucagen Injection market landscape.

Xeris Pharmaceuticals is a key player in the Glucagen Injection market, known for its innovation in diabetes care. The company specializes in developing and commercializing ready-to-use, liquid-stable glucagon formulations, addressing the critical need for emergency hypoglycemia treatment. Xeris focuses on advancing patient-centric solutions, enhancing the ease of glucagon administration. With a commitment to diabetes management, Xeris' products, including GVOKE HypoPen, offer simplicity and accessibility. The company's strategic emphasis on product development, partnerships, and market expansion positions Xeris Pharmaceuticals as a significant contributor to the evolving landscape of the Glucagen Injection market.

**Key Companies in the Glucagen Injection market include**

**Glucagen Injection Industry Developments**

**June 2022:**Gulf Pharmaceutical Industries (Julphar) and Hangzhou Zhongmei Huadong Pharmaceutical Co. have jointly declared a strategic collaboration focused on the development, manufacturing, and commercialization of Liraglutide, encompassing both diabetes and obesity indications. This partnership extends to 17 countries within the Middle East and North Africa region (MENA), including the UAE.

**May 2022:**The US FDA has granted approval to Eli Lilly and Company for Mounjaro (tirzepatide) injection as an adjunct to diet and exercise, aiming to improve glycemic control in adult patients with type 2 diabetes. Mounjaro, a singular molecule, is a weekly administered glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

## **Glucagen Injection Market Segmentation**

### **Glucagen Injection Application Outlook**

### **Glucagen Injection Age Group Outlook**

### **Glucagen Injection Route of Administration Outlook**

### **Glucagen Injection Distribution Channel Outlook**

### **Glucagen Injection Regional Outlook**

## Market Drivers

### Rising Prevalence of Hypoglycemia

The increasing prevalence of hypoglycemia among diabetic patients is a crucial driver for the Glucagen Injection Market. As diabetes rates continue to rise, the incidence of hypoglycemic episodes also escalates, necessitating effective treatment options. Reports indicate that approximately 30% of individuals with diabetes experience hypoglycemia at least once a year. This growing need for rapid intervention has led to a heightened demand for Glucagen injections, which serve as a vital rescue medication. The Glucagen Injection Market is thus positioned to expand as healthcare providers emphasize the importance of immediate access to glucagon for patients at risk. Furthermore, the rising awareness of hypoglycemia management among patients and caregivers is likely to contribute to market growth, as more individuals seek out effective solutions.

### Growing Focus on Diabetes Management

The increasing emphasis on comprehensive diabetes management is a significant driver for the Glucagen Injection Market. Healthcare systems worldwide are prioritizing effective management strategies to mitigate complications associated with diabetes, including hypoglycemia. This focus has led to the integration of glucagon injections into diabetes care plans, promoting their use as essential tools for managing severe hypoglycemic events. Market data suggests that the demand for glucagon products is expected to rise as healthcare providers advocate for proactive measures in diabetes management. Furthermore, educational initiatives aimed at both patients and healthcare professionals are likely to enhance understanding and utilization of Glucagen injections, thereby fostering market growth. The Glucagen Injection Market stands to benefit from this trend as more individuals recognize the importance of having glucagon readily available.

### Advancements in Glucagon Formulations

Innovations in glucagon formulations are significantly influencing the Glucagen Injection Market. Recent developments have led to the creation of more stable and user-friendly glucagon products, which enhance patient compliance and ease of use. For instance, the introduction of pre-filled syringes and auto-injectors has simplified the administration process, making it more accessible for patients and caregivers. This shift towards more convenient delivery systems is expected to drive market growth, as it addresses the challenges associated with traditional glucagon kits. Additionally, the potential for new formulations that require less stringent storage conditions may further expand the market by increasing the availability of Glucagen injections in various settings, including emergency situations. As these advancements continue to emerge, they are likely to reshape the landscape of the Glucagen Injection Market.

### Increased Investment in Diabetes Research

The surge in investment directed towards diabetes research is poised to impact the Glucagen Injection Market positively. As pharmaceutical companies and research institutions allocate resources to develop innovative diabetes treatments, the focus on glucagon therapies is likely to intensify. This influx of funding may lead to breakthroughs in glucagon formulations and delivery methods, enhancing the overall efficacy and appeal of Glucagen injections. Additionally, collaborations between academia and industry are expected to yield new insights into the mechanisms of hypoglycemia, further driving the demand for glucagon products. The Glucagen Injection Market could experience substantial growth as these advancements translate into improved treatment options for patients, ultimately addressing the pressing need for effective hypoglycemia management.

### Rising Awareness of Emergency Preparedness

The growing awareness surrounding emergency preparedness for diabetes patients is a vital driver for the Glucagen Injection Market. As more individuals and families recognize the importance of being equipped to handle severe hypoglycemic episodes, the demand for Glucagen injections is likely to increase. Educational campaigns and advocacy efforts have played a significant role in promoting the necessity of having glucagon on hand, particularly for those at risk of hypoglycemia. Market data indicates that a substantial percentage of patients are now more informed about the potential dangers of hypoglycemia and the role of glucagon in emergency situations. This heightened awareness is expected to translate into increased sales of Glucagen injections, as patients and caregivers prioritize preparedness in their diabetes management strategies.

## Future Outlook

The Glucagen Injection Market is projected to grow at a 5.63% CAGR from 2025 to 2035, driven by increasing diabetes prevalence, technological advancements, and rising awareness of hypoglycemia management.

**New opportunities:**

- Expansion into emerging markets with tailored distribution strategies. Development of combination therapies integrating Glucagen with other diabetes medications. Investment in digital health platforms for remote patient monitoring and education.

By 2035, the Glucagen Injection Market is expected to achieve robust growth and enhanced market penetration.

## Segment Insights

### By Application: Therapeutic Purpose (Largest) vs. Diagnostics Purpose (Fastest-Growing)

In the Glucagen Injection Market, the therapeutic purpose segment occupies the largest market share, reflecting its established role in treating severe hypoglycemia and other critical health conditions. This segment's dominance is attributed to its widespread acceptance among healthcare providers and patients, emphasizing its reliability and effectiveness in emergency scenarios. On the other hand, the diagnostics purpose segment is emerging as a fast-growing area, driven by the increasing use of glucagon in diagnostic procedures, which enhances its utility in medical settings and expands its market presence. Growth trends reveal that the therapeutic purpose segment benefits from ongoing advancements in treatment protocols and increasing awareness of severe hypoglycemia's impacts. Importantly, the diagnostics purpose segment is witnessing rapid development fueled by technological innovations and growing research and development activities related to glucagon's role in diagnostic applications. This dual increase underscores a dynamic shift in the Glucagen Injection Market as healthcare systems adapt to evolving needs.

Therapeutic Purpose (Dominant) vs. Diagnostics Purpose (Emerging)

The therapeutic purpose segment of the Glucagen Injection Market serves as a cornerstone for medical interventions, primarily focused on addressing severe hypoglycemia. This segment is characterized by its well-established protocols in emergency situations, with healthcare professionals being trained to administer glucagon effectively, thereby reinforcing its dominance. Conversely, the diagnostics purpose segment is on the rise, labeled as emerging due to its evolving applications in medical diagnostics, including its use in assessing adrenal insufficiency and other conditions. The growing recognition of glucagon's versatility in various diagnostic contexts is driving this segment's market expansion, highlighting its potential to capture attention in future healthcare solutions.

### By Age Group: Paediatrics (Largest) vs. Adults (Fastest-Growing)

The Glucagen Injection Market exhibits a notable distribution in terms of age groups, with the paediatric segment commanding the largest share. This segment is primarily driven by increasing incidences of hypoglycemia in children and the growing awareness among caregivers regarding diabetes management in younger populations. Meanwhile, the adult segment is witnessing significant growth, fueled by rising lifestyle-related health issues, increasing prevalence of diabetes, and a growing emphasis on preventive healthcare. This shift indicates a dynamic market landscape that is evolving with changing health paradigms.

Paediatrics: Dominant vs. Adults: Emerging

In the Glucagen Injection Market, the paediatrics segment stands out as the dominant force, characterized by its established protocols for emergency management of hypoglycemia in child patients. Pediatricians and healthcare providers are increasingly adopting Glucagen for its efficacy and convenience, contributing to its strong market position. On the other hand, the adult segment is recognized as emerging, with rapid growth driven by a rise in diabetes cases among adults due to factors like sedentary lifestyles and poor nutrition. This segment's emerging status reflects the increasing need for effective treatments in adults, leading to heightened interest from manufacturers and healthcare providers in developing tailored solutions.

### By Route of Administration: Subcutaneous (Largest) vs. Intramuscular (Fastest-Growing)

In the Glucagen Injection Market, the route of administration plays a crucial role in shaping patient and healthcare provider choices. Subcutaneous administration holds the largest market share, favored for its accessibility and ease of use in both clinical and home settings. The intramuscular route, meanwhile, is segmenting its presence by gaining attention, particularly in emergency and outpatient care, reflecting a growing preference among healthcare professionals. The growth trends within this segment are notably influenced by increasing awareness surrounding glucagon as a critical emergency treatment for severe hypoglycemia. Furthermore, innovations in injection devices that facilitate intramuscular administration are emerging as potent drivers of market growth, alongside a rise in diabetes incidence which propels demand for glucagon injections across various patient demographics.

Subcutaneous (Dominant) vs. Intramuscular (Emerging)

Subcutaneous administration of Glucagen injections is currently the dominant method due to its simplicity and effectiveness. It offers patients a convenient option for self-administration, encapsulating the need for ease-of-use and comfort. Subcutaneous injections are also associated with a reduced risk of complications compared to other methods, such as intravenous administration. On the other hand, the intramuscular route is emerging as a strong contender in specific scenarios, particularly for rapid interventions required in emergency settings. Intramuscular glucagon is favored for its faster onset of action, making it essential in critical hypoglycemic situations. As healthcare systems adapt to the rising prevalence of diabetes, both routes must align with patients' needs, enhancing their market positions.

### By Distribution Channel: Hospital Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

In the Glucagen Injection Market, hospital pharmacies hold the largest share, reflecting their critical role in providing essential medications to patients during hospital visits and emergencies. Retail pharmacies also contribute significantly to the market, serving a broad customer base and facilitating easy access to Glucagen injections for chronic conditions. Online pharmacies are gaining traction by offering convenience and competitive pricing, appealing especially to tech-savvy consumers who prefer digital solutions for their healthcare needs.

Pharmacies: Hospital (Dominant) vs. Online (Emerging)

Hospital pharmacies dominate the Glucagen Injection Market due to their essential role in inpatient care, where immediate access to medications is crucial. They often stock a comprehensive range of injectable pharmaceuticals, ensuring that healthcare providers can deliver timely interventions, particularly in emergencies. On the other hand, online pharmacies represent the emerging segment, capitalizing on digital trends and the shift towards e-commerce in healthcare. They offer patients the convenience of ordering medications from home, often providing lower prices than traditional retail outlets. This shift is driven by increased internet penetration and the growing acceptance of online health services, making them a vital part of the future pharmaceutical landscape.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for Glucagen injections, accounting for approximately 45% of the global market share. The region's growth is driven by increasing diabetes prevalence, advancements in healthcare technology, and supportive regulatory frameworks. The demand for effective diabetes management solutions is further fueled by rising awareness and education about the disease. Regulatory catalysts, such as streamlined approval processes for new drugs, enhance market dynamics. The United States is the leading country in this region, with significant contributions from major players like Eli Lilly and Company, Pfizer, and Amgen. Canada also plays a vital role, although its market share is smaller. The competitive landscape is characterized by strong R&D investments and strategic partnerships among key players, ensuring a robust supply of innovative products to meet the growing demand.

### Europe : Emerging Market with Growth Potential

Europe is witnessing a growing demand for Glucagen injections, holding approximately 30% of the global market share. The region's growth is driven by increasing diabetes cases, an aging population, and favorable healthcare policies. Countries like Germany and France are at the forefront, supported by regulatory initiatives that promote access to essential medications. The European Medicines Agency (EMA) continues to play a crucial role in ensuring the safety and efficacy of diabetes treatments, fostering market growth. Germany is the largest market in Europe, followed closely by France and the UK. The competitive landscape features key players such as Sanofi and Boehringer Ingelheim, which are actively involved in product innovation and market expansion. The presence of strong healthcare infrastructure and increasing investments in diabetes care further enhance the region's market potential, making it a significant player in the global landscape.

### Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is emerging as a significant market for Glucagen injections, accounting for about 20% of the global market share. The region faces a rising diabetes epidemic, driven by urbanization, lifestyle changes, and increasing healthcare access. Countries like China and India are experiencing rapid growth in demand for diabetes management solutions, supported by government initiatives aimed at improving healthcare infrastructure and access to medications. China is the largest market in the region, with India following closely. The competitive landscape is evolving, with both local and international players, including Novo Nordisk and Mylan, striving to capture market share. The presence of a large patient population and increasing awareness about diabetes management are key factors driving growth in this region, making it a focal point for future investments in healthcare solutions.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the Glucagen injection market, holding approximately 5% of the global market share. The growth is primarily driven by increasing diabetes prevalence, urbanization, and improving healthcare systems. Countries like South Africa and the UAE are leading the way, with government initiatives aimed at enhancing diabetes care and access to essential medications. The region's regulatory environment is evolving, which is expected to facilitate market entry for new products. South Africa is the largest market in this region, with a growing number of healthcare facilities and increasing awareness about diabetes management. The competitive landscape is characterized by a mix of local and international players, including key companies like Pfizer and Amgen. As healthcare infrastructure continues to improve, the region presents significant opportunities for growth in the Glucagen injection market, attracting investments from various stakeholders.

## Competitive Benchmarking

Leading market players in the Glucagen Injection Market are focused on strategic initiatives such as product development, geographic expansion, and collaborations. These companies actively engage in research and development to enhance glucagon formulations and delivery methods. Marketing developments emphasize the importance of Glucagen in diabetes emergency care. Collaborations with healthcare providers and institutions enhance the overall competitiveness. Efforts are directed towards maintaining product quality, meeting regulatory standards, and expanding market reach, ensuring a strong presence in the evolving landscape of the Glucagen Injection Market. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Glucagen Injection industry to benefit clients and increase the market sector. In recent years, the Glucagen Injection industry has offered some of the most significant advantages to medicine. Major players in the Glucagen Injection Market, including General Mills Inc., Amway, Conagra Brands Inc., Cargill Incorporated, Abbott Laboratories, Kraft Foods Group Inc., and others, are attempting to increase market demand by investing in research and development operations. Novo Nordisk is a major player in the Glucagen Injection Market, emphasizing its commitment to [diabetes care](../../../reports/needle-free-diabetes-care-market-912). As a leading pharmaceutical company, Novo Nordisk produces GlucaGen, a glucagon injection used for emergency treatment of severe hypoglycemia in individuals with diabetes. The company's business strategy involves continuous research and development, ensuring product quality, and expanding its global presence. Novo Nordisk's comprehensive approach to diabetes management, including emergency interventions like GlucaGen, solidifies its position in the market. The company's dedication to innovation, patient-centric solutions, and collaborative efforts with healthcare professionals contribute to its significant role in shaping the Glucagen Injection Market landscape. Xeris Pharmaceuticals is a key player in the Glucagen Injection Market, known for its innovation in diabetes care. The company specializes in developing and commercializing ready-to-use, liquid-stable glucagon formulations, addressing the critical need for emergency hypoglycemia treatment. Xeris focuses on advancing patient-centric solutions, enhancing the ease of glucagon administration. With a commitment to diabetes management, Xeris' products, including GVOKE HypoPen, offer simplicity and accessibility. The company's strategic emphasis on product development, partnerships, and market expansion positions Xeris Pharmaceuticals as a significant contributor to the evolving landscape of the Glucagen Injection Market.

## Recent News & Developments

**June 2022:**Gulf Pharmaceutical Industries (Julphar) and Hangzhou Zhongmei Huadong Pharmaceutical Co. have jointly declared a strategic collaboration focused on the development, manufacturing, and commercialization of Liraglutide, encompassing both diabetes and obesity indications. This partnership extends to 17 countries within the Middle East and North Africa region (MENA), including the UAE.

**May 2022:**The US FDA has granted approval to Eli Lilly and Company for Mounjaro (tirzepatide) injection as an adjunct to diet and exercise, aiming to improve glycemic control in adult patients with type 2 diabetes. Mounjaro, a singular molecule, is a weekly administered [glucose](https://www.marketresearchfuture.com/reports/glucose-market-11828)-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

## Report Scope

| MARKET SIZE 2024 | 0.2641(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.279(USD Billion) |
| MARKET SIZE 2035 | 0.4825(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.63% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novo Nordisk (DK), Sanofi (FR), Eli Lilly and Company (US), Boehringer Ingelheim (DE), Pfizer (US), Amgen (US), Bristol-Myers Squibb (US), Mylan (US) |
| Segments Covered | Application, Age group, Route of Administration, Distribution Channel, Region |
| Key Market Opportunities | Increasing prevalence of diabetes drives demand for Glucagen Injection in emergency hypoglycemia treatment. |
| Key Market Dynamics | Rising demand for Glucagen Injection driven by increasing prevalence of diabetes and hypoglycemia management needs. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current market valuation of the Glucagen Injection Market?**
A: As of 2024, the Glucagen Injection Market was valued at 0.2641 USD Billion.

**Q: What is the projected market size for the Glucagen Injection Market by 2035?**
A: The market is projected to reach 0.4825 USD Billion by 2035.

**Q: What is the expected CAGR for the Glucagen Injection Market during the forecast period?**
A: The expected CAGR for the Glucagen Injection Market from 2025 to 2035 is 5.63%.

**Q: Which companies are the key players in the Glucagen Injection Market?**
A: Key players include Novo Nordisk, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Amgen, Bristol-Myers Squibb, and Mylan.

**Q: How does the market segment for therapeutic purposes compare to diagnostics purposes?**
A: In 2024, the therapeutic purpose segment was valued at 0.158 USD Billion, while the diagnostics purpose segment was valued at 0.1061 USD Billion.

**Q: What are the projected values for the pediatric and adult age groups in the Glucagen Injection Market?**
A: The pediatric segment is expected to grow from 0.0792 USD Billion to 0.1485 USD Billion, while the adult segment is projected to increase from 0.1849 USD Billion to 0.334 USD Billion.

**Q: What routes of administration are available for Glucagen Injection?**
A: The market segments for routes of administration include subcutaneous, intramuscular, and intravenous, with respective values of 0.0792, 0.1055, and 0.0794 USD Billion in 2024.

**Q: How are Glucagen injections distributed across different channels?**
A: Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, with 2024 values of 0.105 USD Billion, 0.09 USD Billion, and 0.0691 USD Billion, respectively.

**Q: What trends are influencing the growth of the Glucagen Injection Market?**
A: The growth appears to be driven by increasing demand for diabetes management and advancements in drug delivery systems.

**Q: What implications does the projected market growth have for stakeholders?**
A: The anticipated growth suggests potential opportunities for stakeholders to invest in research and development, particularly in innovative delivery methods.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/glucagen-injection-market-20665*